RA
PCRX icon

Royce & Associates’s Pacira BioSciences PCRX Stock Holding History

Royce & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,803
Closed -$209K – 923
2023
Q3 		$209K Sell
6,803
-117,579
-95% -$4.24M ﹤0.01% 873
2023
Q2 		$4.98M Buy
+124,382
New +$5.14M 0.05% 493
2021
Q2 		– Sell
-115,157
Closed -$8.07M – 1036
2021
Q1 		$8.07M Sell
115,157
-41,933
-27% -$3M 0.05% 501
2020
Q4 		$9.4M Buy
157,090
+3,647
+2% +$214K 0.08% 388
2020
Q3 		$9.22M Sell
153,443
-11,857
-7% -$689K 0.1% 303
2020
Q2 		$8.67M Buy
165,300
+164,426
+18,813% +$6.87M 0.1% 304
2020
Q1 		$29K Buy
874
+58
+7% +$2.41K ﹤0.01% 1072
2019
Q4 		$37K Sell
816
-244
-23% -$10.4K ﹤0.01% 1067
2019
Q3 		$40K Buy
+1,060
New +$42.3K ﹤0.01% 1075

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return